1. Globocan Database. IARC. 2012 (http://globocan.iarc.org/).
2. Siegel RL, Ma J, Zou Z, Jemal A. Cancer Statistics 2014. CA Cancer J Clin 2015, 64:9-29
3. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. CA Cancer J Clin 2018, 68:7-30.
4. Malvezzi M., Bertuccio P., Levi F., La Vecchia C., and Negri E. European cancer mortality predictions for the year 2014. Annals of Oncology 2014, pp. 1-7.
5. Burris HA 3rd, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15 (6): 2403-2413.
6. Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364 (19): 1817-1825.
7. Von Holf DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nabpaclitaxel and gemcitabine. N Eng J Med 2013; 369:1691-1703
8. Tobita, K.; Kijima, H.; Dowaki, S.; Kashiwagi, H.; Ohtan,i Y.; Oida, Y.; Yamazaki, H.; Nakamura, M.; Ueyama, Y.; Tanaka, M.; Inokuchi, S.; Makuuchi, H. Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int. J. Mol. Med. 2003, 11:305-309.
9. Korc, M., Chandrasekar B., Yamanaka Y, Friess H, Buchler M, Beger HG. Overexpression of EGFR in human pancreatic cancer is associated with concomitant increases in the levels of Epidermal Growth Factor and Transforming Growth Factor Alpha. J Clin. Invest. 1992, 90, 13521360 (http://www.jci.org).
10. Cook N., Frese KK, and Moore M. Assessing the role of the EGFR in the development and progression of pancreatic cancer. Gastrointestinal Cancer, Targets and Therapy 2014, 4, 23-37.
11. Burris H and Rocha Lima C. New therapeutic directions for advanced pancreatic cáncer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways. The Oncologist 2008; 13:289-298.
12. Ueda, S.; Ogata, S.; Tsuda, H.; Kawarabayashi, N.; Kimura, M.; Sugiura, Y.; Tamai, S.; Matsubara, O.; Hatsuse, K.; Mochizuki, H. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: Poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004, 29, e1-e8.
13. Korc, M.; Meltzer, P.; Trent, J. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc. Natl. Acad. Sci. USA 1986, 83:5141-5144.
14. Shimizu, N.; Kondo, H.; Gamou, M.A.; Behzadian, A.; Shimizu, Y. Genetic analysis of hyper production of epidermal growth factor receptors in human epidermoid carcinoma a431 cells. Somatic Cell Mol. Genet. 1984, 10:45-53.
15. Watanabe, M.; Nobuta, A.; Tanaka, J.; Asaka, M. An effect of k-ras gene mutation on epidermal growth factor receptor signal transduction in panc-1 pancreatic carcinoma cells. Int. J. Cancer 1996, 67:264-268.
16. Marchetti, A.; Martella, C.; Felicioni, L.; Barassi, F.; Salvatore, S.; Chella, A.; Camplese, P.P.; Iarussi, T.; Mucilli, F.; Mezzetti, A.; Cuccurullo, F.; Sacco, R.; Buttitta, F. Egfr mutations in nonsmall-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 2005, 23:857-865.
17. Tsao, M.S.; Sakurada, A.; Cutz, J.C.; Zhu, C.Q.; Kamel-Reid, S.; Squire, J.; Lorimer, I.; Zhang, T.; Liu, N.; Daneshmand, M.; Marrano, P.; da Cunha Santos, G.; Lagarde, A.; Richardson, F.; Seymour, L.; Whitehead, M.; Ding, K.; Pater, J.; Shepherd, F.A. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 2005, 353:133-144.
18. Immervoll, H.; Hoem, D.; Kugarajh, K.; Steine, S.J.; Molven, A. Molecular analysis of the EGFR-ras-raf pathway in pancreatic ductal adenocarcinomas: Lack of mutations in the BRAF and EGFR genes. Virchows Arch. 2006, 448:788-796.
19. Lee, J.; Jang, K.T.; Ki, C.S.; Lim, T.; Park, Y.S.; Lim, H.Y.; Choi, D.W.; Kang, W.K.; Park, K.; Park, J.O. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and kras mutations on survival of pancreatic adenocarcinoma. Cancer 2007, 109:1561-1569.
20. Russo, A., Rizzo, S., Bronte, G., Silvestris, N., Colucci, G., Gebbia, N., Bazan, V., Fulfaro, F. The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway. Oncology 2009;77(suppl 1):57–68.
21. da Cunha Santos, G.; Dhani, N.; Tu, D.; Chin, K.; Ludkovski, O.; Kamel-Reid, S.; Squire, J.; Parulekar, W.; Moore, M.J.; Tsao, M.S. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National cancer institute of canada clinical trials group study pa.3. Cancer 2010, 116:5599-5607.
22. Boeck, S.H.; Vehling-Kaiser, U.; Waldschmidt, D.; Kettner, E.; Marten, A.; Winklemann, C.; Klein, S.; Kojouharoff, G.; Jung, A.; Heinemann, V. Gemcitabine Plus Erlotinib (GE) Followed by Capecitabine (C) Versus Capecitabine Plus Erlotinib (CE) Followed by Gemcitabine (G) in Advanced Pancreatic Cancer (APC): A Randomized, Cross-Over Phase III Trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO); In ASCO Annual Meeting Proceedings, Chicago, IL, USA, 4–8 June 2010; J. Clin. Oncol. Chicago 2010, p. LBA4011.
23. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Pérez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor – Recovery of antagonistic activity. Immunotechnology 1997; 3:71-81.
24. Fernandez A, Spitzer E, Perez R, Boehmer FD, Eckert K, Zschiesche W, Grosse R. A new monoclonal antibody for detection of EGF-receptors in western blots and paraffin-embedded tissue sections. J Cell Biochem 1992; 49:157-165.
25. Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative antiangiogenic and proapoptotic activity of h-R3-A humanized anti-EGFR antibody. Int J Cancer 2002; 101:567-575.
26. Strumberg D., Schultheis B., Scheulen M.E., Hilger R.A., Krauss J., Marschner N., Lordick F., Bach F., Reuter D, Edler L., and Mross K. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs 2012, 30(3):1138-1143.
27. Schultheis B., Strumberg D., Ebert M.P. et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Ann Oncol. 2017; 28: 2429–2435.
28. D`Andrea GM. Use of antioxidants during chemotherapy and radiotherapy should be avoide. Cancer J Clin. 2005; 55:319-21.
29. Prasad KN, Cole WC. Antioxidants in chemotherapy. J Clin Oncol. 2006;24(6):8-9.
30. Núñez Sellés AJ. Terapia antioxidante, estrés oxidativo y productos antioxidantes: retos y oportunidades. Rev Cubana Salud Pública 2011; 37 supl.5.
31. Juranek I, Bezek S. Controversy of free radical hypothesis: reactive oxygen species-causeor consequence of tissue injury? Gen Physiol Biophys. 2005; 24:263-78.
32. Galati G, O'Brien PJ. Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Radic Biol Med. 2004; 37:287-303.
33. Hasnian BJ, Mooradian AD. Recent trials of antioxidant therapy: What should we be telling our patients? Clev Clin J Med. 2004;71(4):327-334.
34. Núñez Sellés AJ. Antioxidants theraphy: Myth or reality? J Braz Chem Soc. 2005; 16:699710.
35. Bjelakovic G, Nikolova D, Lotte-Gluud L, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention. JAMA. 2007; 297:842-57.
36. Lamson DW, Brignall MS. Natural agents in the prevention of cancer, part two: preclinical data and chemoprevention for common cancers. Altern Med Rev. 2001; 6(2):167-87.
37. BlockK I, KochA C, MeadM N, TothyP K, NewmanR A, GyllenhaalC, . Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. Cancer Treatment Reviews 2007; 33(5):407-418.
38. Prasad K: Modulation of the effect of tumor therapeutic agents by vitamin C. Life Sci. 1980;27:275-80.
39. Prasad KN, Hernández C, Edwards-Prasad J, Nelson J, Borus T,Robinson WA: Modification of the effect of tamoxifen, cis-platin, DTIC, and interferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins. Nutr Cancer 1994; 22:233–245.
40. Milkovic L, Siems W, Siems R and Zarkovic N. Oxidative stress and antioxidants in carcinogenesis and integrative therapy of cancer. Curr Pharm Des. 2014; 20:6529-6542.
41. Rodríguez MJ, Bouyon A, Alexandre J. Role of antioxidant complements and supplements in oncology in addition to an equilibrate regimen: a systematic review. Bull Cancer. 2009 Jun; 96(6):677-84.
42. Khan N. Cancer Chemoprevention through Dietary Antioxidants: Progress and Promise. ANTIOXIDANTS & REDOX SIGNALING 2008;10(3):475-510.
43. Bardia A, Tleyjeh IM, Cerhan JR, Sood AK, Limburg PJ, Erwin PJ, Montori VM. Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and meta-analysis. Mayo Clin Proc. 2008 Jan; 83(1):23-34.; 27:275–80.
44. Oncoxin® un producto esencial para la práctica oncológica. Manual del producto.
45. Revista Digital Discovery DSalud. El tratamiento del cáncer con antivíricos y antioxidantes. 2004 mayo Número 61. Disponible en: http://www.dsalud.com/reportaje/el_tratamiento_del_càncer_con_antivìricos_y_antioxidantes
46. Vilar-Gómez E et al. Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C. World J Gastroenterol 2010 June 7; 16(21): 2638-2647.
47. Vilar-Gomez E et al. Viusid, a nutritional supplement, in combination with interferona-2b and ribavirin in patients with chronic hepatitis Liver International 247-59. 2007.
47. Hernández-García S, González V, Sanz E, Pandiella A. Effect of Oncoxin Oral Solution in HER 2-Overexpressing breast cáncer. Nutr Cancer. 2015;67(7):1159-69.
48. Díaz Rodríguez E, Hernández García S, Sanz E, Pandiella A. Antitumoral effect of Oncoxin on acute myeloid leukemia. Oncotarget 2016;7(5):6231-6242.
49. Hernández-Unzueta I, Benedicto A, Olaso E, Sanz E, Viera C, Arteta B et al. Oncoxin Oral Solution as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver. Oncology letters 2017; 13:4002-4012.
50. Yang CS. Inhibition of carcinogenesis by tea. Nature 1997;389(6647):134-135.
51. Tachibana H, Kogak, Fujimura Y, Yamada K. Areceptor for Green tea polyphenol EGCG. Nature Structural and Molecular Biology 2004,11(4):380-381.
52. Jankun J, Selman SH, Swiercz R, Skrzypczak E. Nature 1997;561(6633). Disponible en: http//: www.nature.com/nature/journal/v387/n6633/full/387561a0.html. Consultado el 7/08/2017.
53. Editorial. A teacupful of medicine? Nature Structural and Molecular Biology June 2008;15(6):537.
54. Siddiqui IA, Asim M, Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H.Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. The FASEB Journal April 2011;25(4):1198-1207.
55. Milligan SA, Burke P, Coleman DT, Bigelow RL, Steffan JJ, Jennifer L et al. The Green Tea Polyphenol EGCG Potentiates the Antiproliferative Activity of c-Met and Epidermal Growth Factor Receptor Inhibitors in Non–small Cell Lung Cancer Cells. Clin Cancer Res August 1 2009;15 (15): 4885-4894.
56. Chenggang Y, Du W, Yang D. Inhibition of green tea polyphenol EGCG-epigallocatechin-3gallate) on the proliferation of gastric cancer cells by suppressing canonical wnt/β-catenin signalling pathway. International Journal of Food Sciences and Nutrition 2016;67(7):818-827.
57. Hernández-Unzueta I, Benedicto A, Olaso E, Sanz E, Viera C, Arteta B et al. Ocoxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver. Oncol Lett. 2017 Jun; 13(6): 4002–4012.
58. Maruyama T, Murata S, Nakayama K, Sano N, Ogawa K, Nowatari T, et al. Epigallocatechin3-gallate suppresses liver metastasis of human colorectal cancer. Oncol Rep. 2014 Feb;31(2):625-33.
59. Roomi MW, Roomi N, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M. Inhibition of pulmonary metastasis of melanoma b16fo cells in C57BL/6 mice by a nutrient mixture consisting of ascorbic Acid, lysine, proline, arginine, and green tea extract. Exp Lung Res. 2006 Nov-Dec;32(10):51.
60. Delgado Morales JC, Campbell Miñoso M, Páez Mena O, Orellana Alvarado MR, Linares Vizcaíno I. Efficacy of Oncoxin Plus Viusid in the Treatment of Rheumatoid Arthritis. Bioportfolio. 2014;14(11):39. Accesible en: http://www.bioportfolio.com/resources/trial/73184/Efficacy-ofOncoxin-Plus-Viusid-in-the-Treatment-of-Rheumatoid-Arthritis.html
61. Vilar Gómez E, Martínez Pérez Y, Vega Sánchez H, Riverón Forment G, Arus Soler E, Calzadilla Bertot L et al. Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C. World J Gastroenterol 2010 June 7;16(21): 2638-2647.
62. Vilar Gómez E, Sánchez Rodríguez Y, Torres González A, Calzadilla Bertot L, Arus Soler E, Martínez Pérez Y et al. Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis. A randomised and controlled trial. BMJ Open 2011. Disponible en: http:// bmjopen.bmj.com
63. Asociación Médica Mundial. Declaración de Helsinki de la AMM - Principios éticos para las investigaciones médicas en seres humanos. Adoptada por la 18ª Asamblea Médica Mundial (Helsinki, 1964) y enmendada por novena ocasión en la 64ª Asamblea General, Fortaleza, Brasil (octubre, 2013). Disponible en: http://www.wma.net/es/30publications/10policies/b3/ Accedido: 13/09/17.
64. Hernández Unzueta I, Benedicto A, Olaso E, Sanz E, Viera C, Arteta B et al. Ocxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cáncer to the liver. Oncology Letters 2017; 13: 4002-4012.
65. Stanculeanu D, Gheorghi G, Dragusanu D. Estudio clínico realizado en cáncer de mama, cabeza-cuello y cuello de útero. Comunicación Personal.
66. Serykh B, Kaliuzgina M, Pavlenco O, BuldacovaO, Starojo V. Estudio clínico en pacientes con carcinoma de estómago e intestino grueso durante 3 meses. Disponible en: http://www.eurolife.com.co/catalisys/ocoxin/cancer_estomago.pdf 67. Gray Lovio O, Abreu A. Cáncer de piel en Cuba: Incidencia y terapéutica alternativa. Trabajo presentado en XIX Congreso Ibero Latinoamericano de Dermatología. Sevilla, 2012. Disponible en: http://www.eurolife.com.co/catalisys/ocoxin/CANCER%20DE%20PIEL%20CUBA.pdf.
68. Benedicto A, Hernández-Unzueta I, Romayor I, et al. Ocoxin oral solution exerts antitumor effect and improves chemotherapy reducing stromal cell-mediated resistance in pancreatic cell lines in vitro. Poster presentado en: 1st Joint Congress of the Spanish Societies for Cell Biology, Genetics and Developmental Biology. October 24-27th, 2017. Gijón, España.
